Research Status And Development Trend Of Monoclonal Antibodies For Non-Small Cell Lung Cancer

Abstract

Lung cancer remains the leading cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) accounting for 80% of cases. Traditional chemotherapy faces limitations such as non-specific cytotoxicity, transient efficacy, and resistance due to tumor heterogeneity. Monoclonal antibodies (mAbs) have emerged as transformative agents, offering targeted therapy with improved specificity and reduced toxicity. Recent advancements include immune checkpoint inhibitors anti-angiogenic agent, and innovative formats such as antibody-drug conjugates (ADCs) and bispecific antibodies. Despite progress, challenges persist in overcoming resistance mechanisms, optimizing combination therapies, and expanding biomarker-driven approaches. This article analyzes the evolution of mAbs in NSCLC treatment, focusing on their mechanisms, clinical application, and new developments. The study underscores the role of mAbs in enabling precision medicine through multi-target inhibition, synergistic combinations, and adaptive trial designs. These advancements provide a roadmap for personalized NSCLC management, yet unresolved issues include resistance to EGFR/ALK inhibitors, optimal ADC linker stability, and heterogeneity in treatment response. Future research should prioritize novel targets, integrate multi-omics for biomarker discovery, and refine immunomodulatory strategies to transform NSCLC into a chronic manageable disease.